Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?

Key Takeaways CORT's only drug Korlym generated $351.6M in H1 2025 sales, up 13.2% year over year.Corcept filed an NDA for relacorilant in Cushing's syndrome, with an FDA decision due on Dec. 30, 2025.An NDA for relacorilant with nab-paclitaxel in ovarian cancer has an FDA decision date of July 11, 2026.Corcept Therapeutics’ (CORT) sole-marketed drug, Korlym (mifepristone), is approved for treating Cushing's syndrome or endogenous hypercortisolism. The company’s top line solely comprises product sales from ...